RIBASPHERE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RIBASPHERE (RIBASPHERE).
Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by competing with endogenous nucleotides and interfering with viral polymerase activity. It also has immunomodulatory effects.
| Metabolism | Hepatic metabolism via deribosylation and hydrolysis; not significantly metabolized by CYP450 enzymes. |
| Excretion | Renal (80% unchanged, with remainder as metabolites); biliary/fecal (minor, <10%). |
| Half-life | Terminal elimination half-life: 40-60 hours in patients with normal renal function; prolonged in renal impairment (up to 100 hours). Accumulation occurs with repeated dosing. |
| Protein binding | 60-70% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd: 1.4-1.8 L/kg; indicates extensive tissue distribution, including liver. |
| Bioavailability | Oral bioavailability: 40-70% (increased with high-fat meal). |
| Onset of Action | Oral: 1-2 hours for serum concentration; clinical effect (antiviral) within days to weeks. |
| Duration of Action | Dosing interval is based on half-life; clinical effect persists for weeks after discontinuation. Used in combination with direct-acting antivirals. |
| Molecular Weight | 244.2 |
800-1200 mg/day orally in 2 divided doses for hepatitis C, in combination with peginterferon alfa or other direct-acting antivirals.
| Dosage form | CAPSULE |
| Renal impairment | Creatinine clearance 30-50 mL/min: reduce dose by 50%; <30 mL/min or hemodialysis: contraindicated. |
| Liver impairment | Child-Pugh class A: no adjustment; class B or C: contraindicated. |
| Pediatric use | Weight-based: 15 mg/kg/day orally in 2 divided doses for children ≥3 years with chronic hepatitis C. |
| Geriatric use | No specific adjustments; use caution due to age-related renal impairment and increased risk of adverse effects. |
| 1st trimester | Ribavirin is contraindicated in pregnancy; significant teratogenic and embryocidal effects observed in animal studies. Use in first trimester is absolutely contraindicated. |
| 2nd trimester | Contraindicated; human data show increased risk of birth defects and fetal death. Avoid use in second trimester. |
| 3rd trimester | Contraindicated; ribavirin accumulates in fetal tissues and may cause harm. Not recommended in third trimester. |
Clinical note
Comprehensive clinical and safety monograph for RIBASPHERE (RIBASPHERE).
| Placental transfer | Ribavirin crosses the placenta readily; animal studies show accumulation in fetal tissues. Human studies confirm placental transfer. |
| Breastfeeding | Ribavirin is excreted into breast milk in animal studies; human data are lacking. Due to potential for serious adverse effects in nursing infants, breastfeeding is not recommended during ribavirin therapy and for 2 weeks after last dose. |
■ FDA Black Box Warning
Hemolytic anemia, which may worsen cardiac disease and lead to myocardial infarction; monotherapy is not effective for chronic hepatitis C; must not be used alone.
| Serious Effects |
PregnancyFemales of childbearing potential not using effective contraceptionMale partners of pregnant womenSignificant hemoglobinopathies (e.g., thalassemia major, sickle cell anemia)Autoimmune hepatitisDecompensated cirrhosisHypersensitivity to ribavirin or any component
| Precautions | Hemolytic anemia (requires dose reduction or discontinuation), teratogenicity (pregnancy category X), pancreatitis, pulmonary infiltrates, bone marrow suppression, ophthalmologic effects, thyroid abnormalities, and hypersensitivity reactions. |
| Food/Dietary | Ribasphere should be taken with meals to reduce gastrointestinal side effects such as nausea and diarrhea. Avoid grapefruit and grapefruit juice as they may increase ribavirin levels. No other specific food restrictions; maintain adequate hydration. |
Loading safety data…
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | Ribavirin is contraindicated in pregnancy (FDA Category X). In animal studies, ribavirin has demonstrated significant teratogenic and embryocidal effects at doses well below the recommended human dose. For pregnant women with chronic hepatitis C, therapy with ribavirin is contraindicated. For male patients, ribavirin causes testicular toxicity and may induce sperm abnormalities; it is recommended that female partners of male patients avoid pregnancy during treatment and for 6 months after the last dose due to drug accumulation in sperm. |
| Fetal Monitoring | Pregnancy testing should be performed immediately before initiation of therapy, monthly during treatment, and for 6 months after discontinuation in all female patients of childbearing potential. Two reliable forms of effective contraception must be used during therapy and for 6 months post-treatment. Male patients with female partners of childbearing potential must also use condoms during therapy and for 6 months after treatment. If pregnancy occurs during therapy, the patient should be apprised of the potential hazard to the fetus. |
| Fertility Effects | Ribavirin causes reversible testicular toxicity in animal models, including decreased sperm counts and abnormal sperm morphology. In human males, ribavirin may impair spermatogenesis; sperm abnormalities have been reported. Effects on female fertility are not well characterized, but animal studies show reduced fertility. It is recommended that male patients use contraception during and for 6 months after treatment to avoid potential fetal exposure. |
| Clinical Pearls | Ribasphere (ribavirin) is used in combination with peginterferon alfa for chronic hepatitis C. Monitor hemoglobin closely due to dose-dependent hemolytic anemia. Dose reduction or discontinuation may be required if Hb <10 g/dL. Avoid in patients with hemoglobinopathies (e.g., thalassemia, sickle cell disease). Pregnancy category X; must use two forms of contraception during therapy and for 6 months after. |
| Patient Advice | Take Ribasphere with food to reduce gastrointestinal upset. · Do not become pregnant or father a child during treatment and for 6 months after stopping. Use two reliable birth control methods. · Report symptoms of anemia (fatigue, shortness of breath, pale skin) or new chest pain immediately. · Avoid alcohol completely during treatment as it can worsen liver damage. · Do not stop taking Ribasphere without consulting your doctor, even if you feel well. |